Search results
Showing 1036 to 1050 of 2006 results for nice guidelines
Discontinued Reference number: GID-PHG0
Agenda and papers of the NICE public board meeting on 19 July 2023
Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for plaque psoriasis in children and young people.
Discontinued Reference number: GID-CGWAVE0771
Reducing the mortality and morbidity for healthcare associated infections
Discontinued Reference number: GID-NG10059
NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .
Discontinued Reference number: GID-NG10163
MMprofiler for prognostic risk classification in multiple myeloma (MIB270)
NICE has developed a medtech innovation briefing (MIB) on MMprofiler for prognostic risk classification in multiple myeloma .
AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas (MIB294)
NICE has developed a medtech innovation briefing (MIB) on AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas .
Discontinued Reference number: GID-NG10053
FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)
NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing .
NICE has developed a medtech innovation briefing (MIB) on RenalSense Clarity RMS for acute kidney injury .
In development Reference number: GID-QS10113 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on RT300 for spinal cord injury rehabilitation .